Deciphex is delighted to announce the closing of its first financing with support from key players in the Irish diagnostics industry.

The company simultaneously announced an agreement with a US Clinical Laboratory to supply clinical digital pathology slides.  They have also just inked a deal with a top-5 global pharma collaborator to help develop and evaluate our breakthrough technology in the pre-clinical testing space.   Content is critical, and Deciphex plan to establish one of the world’s largest databases of digital pathology content for machine learning purposes.

“We are really excited with recent developments, we plan to begin scaling our team and proving out the true capabilities of our Patholytix analytical platform” said Dr Donal O’Shea, CEO, “Our collaborators are excited by what they see and are happy to support our ongoing development of what truly is a disruptive technology.”

Deciphex, an Enterprise Ireland High Potential Startup, based in INVENT DCU, Dublin, Ireland, plan to revolutionise pathology through automation of visual examination of tissue.  Founded by former Danaher executives Dr Donal O’Shea and Mark Gregson, our mission is to optimise pathology workflows by helping pathologists focus on critical content.